论文部分内容阅读
产业前瞻我国正在加快生物技术药物的产业化,重点发展针对重大疾病的化学药、中药、生物技术药物新产品,包括临床优势突出的创新中药及个性化治疗药物。生物技术药物将成为我国创新药物的重要来源,其市场份额逐年上升,产品质量和技术水平总体达到国际先进水平。与传统医药产业相比,我国发展现代中药及生物医药技术还有较大的上升空间。到2020年,我国生物医药产业产值规模预计达到1万亿~1.1万亿元,年均增
Industry Prospects China is accelerating the industrialization of biotech drugs, focusing on the development of new products for chemical, traditional Chinese medicine and biotech drugs for major diseases, including innovative Chinese medicine and personalized therapeutic drugs with outstanding clinical advantages. Biotech drugs will become an important source of innovative drugs in our country. Its market share will increase year by year, and its product quality and technical level have reached the international advanced level as a whole. Compared with the traditional pharmaceutical industry, there is still much room for growth in developing modern Chinese medicine and biomedicine technology. By 2020, the output value of bio-pharmaceutical industry in China is expected to reach 1 trillion to 1.1 trillion yuan, with an average annual increase